Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 304 Stomach Neoplasms 34 Neoplasm Metastasis 24 Neoplasms 16 Colorectal Neoplasms 16 Breast Neoplasms, Male 16 HER2-positive Breast Cancer 11 Inflammatory Breast Neoplasms 10 Triple Negative Breast Neoplasms 9 Esophageal Neoplasms 9 Carcinoma, Non-Small-Cell Lung 8 Brain Neoplasms 8 Rectal Neoplasms 7 Adenocarcinoma 7 Colonic Neoplasms 6 Urinary Bladder Neoplasms 5 Pathologic Complete Response 5 Biliary Tract Neoplasms 5 Urologic Neoplasms 4 Salivary Gland Neoplasms 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Gallbladder Neoplasms 4 Carcinoma, Ductal, Breast 4 Recurrence 3 Pancreatic Neoplasms 3 Neoplastic Cells, Circulating 3 Multiple Myeloma 3 Meningeal Neoplasms 3 HER2-positive Gastric Cancer 3

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unilateral HER2 Positive Breast Cancer × Trastuzumab × Clear all

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡